Early cancer detection startup Craif raises $22M
Cancer ranks as one of the top causes of death worldwide. The National Cancer Institute reported nearly 20 million new cancer cases and 9.7 million cancer-related deaths globally in 2022, with projections showing a rise to 29.9 million new cases by 2040.
Craif, spun off from Nagoya University in Japan in 2018, is using microRNA(miRNA) to develop an AI-powered early cancer detection software, and it has raised $22 million in Series C funding to expand further into the U.S. market and bolster its R&D.
Ryuichi Onose, co-founder and CEO of Craif, told TechCrunch in an interview that the company completed its Series C funding round with a valuation of just under $100 million.
X&KSK, an existing investor, led the latest funding, which brings its total raised to $57 million to date, along with the U.S.-based investor Unreasonable Group, its first investment in a Japanese startup, TAUNS Laboratories, Daiwa House Industry and Aozora Bank Group.
Craif's journey started when Onose saw how deeply cancer affected his family, with both his grandparents being diagnosed with the disease. These personal experiences have inspired a strong commitment to help address the cancer issue. Onose and Takao Yasui, an associate professor at Nagoya University, co-founded Craif just a month after they met. Yasui had created a new method for early cancer detection using urinary biomarkers.
Early detection of a treatable condition can be challenging as traditional diagnostic methods like blood tests can be invasive, causing some people to avoid regular screening, Onose said. In addition, limited access to medical facilities in certain areas makes it challenging for individuals to easily obtain cancer testing, according to Onose.
Craif aims to address these gaps by providing a non-invasive urine-based test that enables early cancer detection, even at a very early stage, like at Stage 1.
'The test can be conducted from the comfort of a patient's home and is powered by advanced microRNA analysis, making early detection more accessible and effective,' Onose said. 'Our users are health-conscious individuals who are concerned about cancer but find it challenging to commit to conventional screenings due to time, cost and accessibility constraints.'
Several startups are creating platforms for early cancer detection in the industry, like Grail, Freenome, DELFI Diagnostics and Clearnote Health.
Craif differentiates itself by using microRNA as a biomarker instead of cfDNA (cell-free DNA) like most competitors and utilizing urine.
'miRNA, which gained heightened recognition after being linked to the 2024 Nobel Prize, is known for its deep involvement in cancer biology even at the earliest stages,' Onose explained. 'Unlike cfDNA, miRNA is proactively secreted by early cancer cells, making it particularly suitable for early cancer detection.'
Another unique aspect of its product is its use of urine. Onose said urine is easy and non-invasive, providing many scientific and practical benefits. It has fewer impurities than other samples, making the biomarker signals clearer, he added. This helps to decrease any measurement errors, like those from hemolysis in blood and saves money on tests.
Craif's first product, miSignal, a test that detects the risk of seven different cancers (pancreatic, colorectal, lung, stomach, esophagus breast, ovarian) using urinary miRNA, is already generating revenues in Japan. The products are distributed through clinics, pharmacies, direct-to-consumer sales, and corporate wellness programs, providing a variety of revenue sources that can be expanded, according to the company CEO.
'We are partnered with over 1000 medical institutions and about 600 pharmacies in Japan, serving about 20,000 users. Our team consists of 73 dedicated employees,' Onose told TechCrunch.
The revenue model offers both single tests and subscription packages for regular testing, with many users opting for subscription plans. It posted $5 million in revenue in 2024 and aims to generate $15 million by the end of this year, Onose told TechCrunch.
Craig intends to broaden the scope of miSignal to include more than ten different types of cancers in the coming year. Moreover, the startup is getting ready to use its technology for the early detection of non-cancerous diseases, such as neurodegenerative disorders like dementia.
Craif has its R&D lab in Irvine, California, and plans to open another office in San Diego to handle its business operations.
The new funding will help the startup enter the U.S. market with its miSingal, aiming to complete trials in the U.S. in 2026-end and get FDA approval as early as 2027.
It has already begun collecting pancreatic cancer samples in collaboration with 30 medical institutions across 15 U.S. states.
This article originally appeared on TechCrunch at https://techcrunch.com/2025/04/27/craif-a-non-invasive-early-cancer-detection-platform-grabs-22m/
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
3 hours ago
- Yahoo
Is Ford's Model e Business Dragging Down its Overall Results?
US Legacy automaker Ford Motor Company F operates a dedicated electric vehicle (EV) segment, Model e, to focus and strategize its efforts toward EVs. The company's Mustang Mach-E and F-150 Lightning EVs have been received well by customers. The segment, however, has failed to generate profits for the company despite continued improvements. After having incurred losses of $4.7 billion in its EV business in 2023, Ford's loss from Model e widened to $5.07 billion in 2024, exacerbated by ongoing pricing pressure and increased investments in next-generation EVs. The segment incurred losses of $849 million in the first quarter of 2025, owing to stiff competition, pricing pressure and significant costs associated with new-generation EV development. The company is expected to incur huge losses in its EV business this year as well. The persisting pricing pressures caused by stiff competition in the industry are significantly ailing margins. China's markets, led by BYD, have been slashing prices, forcing others to follow. The industry also remains prone to supply-chain disruptions. To keep up with the contemporary developments in the industry, Ford has to consistently invest ample amounts. Although the investments are weighing down cash flows, these remain indispensable. Ford is working to improve charging infrastructure throughthe Ford Power Promise campaign, the success of which has already provided customers with a home charger in standard installation. Further plans to drive volumes in the upcoming quarters with recent launches are in place. Toyota Motor Corporation TM, a Japanese auto giant, also remains cautious in its approach toward fully electric vehicles. Toyota's EVs did not constitute more than 1% of its sales globally in fiscal 2025. This has led Toyota to plan on cutting down its EV production target by 20%, reducing from 1.5 million to 1 million units by 2026. However, the company has started to unveil several new EVs. In China, Toyota launched its most affordable EV, the bZ3X, in March, starting at just over $15,000, to regain the market. Honda HMC, TM's closest peer, is also cutting down its EV production as global demand remains stunted. Honda rather seems to shift its focus toward hybrid cars, aiming to launch 13 new hybrid models globally between 2027 and 2030. With rising pressure in China and loosened emission targets in the United States, Honda is expecting a rise in hybrids' popularity, leading to a 30% lowered investment target in EVs. Shares of Ford have lost around 10% year to date against the industry's growth of 11%. Image Source: Zacks Investment Research From a valuation standpoint, F trades at a forward price-to-sales ratio of 0.25, below the industry average. It carries a Value Score of A. Image Source: Zacks Investment Research Take a look at how Ford's EPS estimates have been revised over the past 30 days. Image Source: Zacks Investment Research Ford stock currently carries a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Ford Motor Company (F) : Free Stock Analysis Report Toyota Motor Corporation (TM) : Free Stock Analysis Report Honda Motor Co., Ltd. (HMC) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
4 hours ago
- Yahoo
Japanese AI Unicorn Notta Enters Otter AI's Market with Innovative Smart Voice Recorder
Notta Bets Big on AI Agent-Powered Voice Recorder as Hardware-SaaS Convergence Accelerates TOKYO, June 6, 2025 /PRNewswire/ -- As OpenAI's ChatGPT dominates enterprise AI adoption and Google Gemini reshapes how businesses think about AI assistants, Japanese unicorn Notta announced its ambitious push into the U.S. hardware market with the Notta Memo AI Voice Recorder. From Tokyo to Silicon Valley: The Underdog Story Notta's journey reads like a classic tech disruption playbook, albeit with a Japanese twist. Since launching in 2020, the company has quietly built a formidable AI transcription empire, amassing over 10 million users globally and signing up 4,000 enterprise customers. The real validation? A staggering 68% of Japan's Nikkei 225 companies—the country's most elite corporations—have integrated Notta's AI solutions into their workflows. "Most observers underestimate just how competitive the Japanese enterprise market is," explains industry analyst Sarah from TechInsight Research. "If you can win over two-thirds of the Nikkei 225, you've proven enterprise-grade reliability at scale." Notta's 2022 Airgram acquisition was just the opening move—the company believes the real opportunity lies in completely reimagining how voice technology integrates into daily workflows. Security-First Approach Gives Notta Enterprise Edge Unlike many AI startups that retrofit compliance as an afterthought, Notta built enterprise security into its foundation from day one. The company holds ISO/IEC 27001 and SOC 2 Type II certifications—credentials that remain elusive for many competitors still scrambling to meet Fortune 500 requirements. More critically, Notta has secured the regulatory trifecta that unlocks major markets: GDPR compliance for European expansion, HIPAA certification for healthcare disruption, and CCPA adherence for California's privacy-conscious landscape. This compliance-first strategy positions Notta to compete for high-value enterprise contracts that security-conscious organizations won't trust to less mature platforms. Hardware Meets AI: The Five-Platform Ecosystem Play The Notta Memo distinguishes itself in the crowded voice recording market through its unique five-platform ecosystem integration—seamlessly connecting web, iOS, Android, Chrome extension, and the Memo device itself. This comprehensive approach addresses the fragmented user experience that has long plagued the industry. Unlike traditional voice recording solutions that force users to choose between SaaS flexibility and hardware reliability, Notta Memo delivers both. The device features advanced bone-conduction technology for complete phone call recording, intelligent noise reduction for crystal-clear audio capture, and one-tap synchronization with Notta. "We're not just launching another recording device," said Ryan, CEO of Notta. "We're introducing a complete AI-powered voice ecosystem that adapts to how people work and communicate in today's hybrid world. Our hardware becomes an extension of our proven AI platform that has already transformed millions of meetings worldwide." Beyond recording, Notta Memo is your AI-powered agent and centralized knowledge hub—seamlessly integrated across all your workflows. Competitive Positioning in a Dynamic Market Notta enters the US AI transcription market with an integrated approach that combines software and hardware innovation. While the market includes established players like Otter AI in the SaaS space and Plaud AI in hardware solutions, Notta differentiates itself through its comprehensive platform that leverages AI capabilities refined through years of serving millions of global users. The company acknowledges the challenges in competing against established players with loyal American user bases. However, Notta's proven track record of rapid user acquisition and revenue growth in Japan, combined with its technological differentiation, positions it as a formidable new entrant. Market Timing and Strategic Vision Notta's American expansion comes at a pivotal moment in the AI industry. As enterprises increasingly adopt AI agents for productivity enhancement and consumers demand more intelligent, seamless technology experiences, the convergence of AI SaaS and purpose-built hardware represents a natural evolution. The Notta Memo's launch signals more than just product diversification – it represents Notta's vision of AI-native hardware that thinks, learns, and adapts to user needs. This positions the company at the forefront of the next wave of AI innovation, where the distinction between SaaS and hardware dissolves into unified, intelligent experiences. About Notta Notta is the AI unicorn that's redefining how the world captures and understands conversations. Seamlessly integrating advanced SaaS with intelligent hardware, Notta turns conversations from any meeting, call, or discussion into actionable insights. This AI-powered, end-to-end solution captures and structures spoken interactions, creating a centralized knowledge hub. Media Contact: contact@ View original content to download multimedia: SOURCE Notta
Yahoo
4 hours ago
- Yahoo
Game theory explains why reasonable parents make vaccine choices that fuel outbreaks
When outbreaks of vaccine-preventable diseases such as measles occur despite highly effective vaccines being available, it's easy to conclude that parents who don't vaccinate their children are misguided, selfish or have fallen prey to misinformation. As professors with expertise in vaccine policy and health economics, we argue that the decision not to vaccinate isn't simply about misinformation or hesitancy. In our view, it involves game theory, a mathematical framework that helps explain how reasonable people can make choices that collectively lead to outcomes that endanger them. Game theory reveals that vaccine hesitancy is not a moral failure, but simply the predictable outcome of a system in which individual and collective incentives aren't properly aligned. Game theory examines how people make decisions when their outcomes depend on what others choose. In his research on the topic, Nobel Prize-winning mathematician John Nash, portrayed in the movie 'A Beautiful Mind, showed that in many situations, individually rational choices don't automatically create the best outcome for everyone. Vaccination decisions perfectly illustrate this principle. When a parent decides whether to vaccinate their child against measles, for instance, they weigh the small risk of vaccine side effects against the risks posed by the disease. But here's the crucial insight: The risk of disease depends on what other parents decide. If nearly everyone vaccinates, herd immunity – essentially, vaccinating enough people – will stop the disease's spread. But once herd immunity is achieved, individual parents may decide that not vaccinating is the less risky option for their kid. In other words, because of a fundamental tension between individual choice and collective welfare, relying solely on individual choice may not achieve public health goals. This makes vaccine decisions fundamentally different from most other health decisions. When you decide whether to take medication for high blood pressure, your outcome depends only on your choice. But with vaccines, everyone is connected. This interconnectedness has played out dramatically in Texas, where the largest U.S. measles outbreak in a decade originated. As vaccination rates dropped in certain communities, the disease – once declared eliminated in the U.S. – returned. One county's vaccination rate fell from 96% to 81% over just five years. Considering that about 95% of people in a community must be vaccinated to achieve herd immunity, the decline created perfect conditions for the current outbreak. This isn't coincidence; it's game theory playing out in real time. When vaccination rates are high, not vaccinating seems rational for each individual family, but when enough families make this choice, collective protection collapses. This dynamic creates what economists call a free rider problem. When vaccination rates are high, an individual might benefit from herd immunity without accepting even the minimal vaccine risks. Game theory predicts something surprising: Even with a hypothetically perfect vaccine – faultless efficacy, zero side effects – voluntary vaccination programs will never achieve 100% coverage. Once coverage is high enough, some rational individuals will always choose to be free riders, benefiting from the herd immunity provided by others. And when rates drop – as they have, dramatically, over the past five years – disease models predict exactly what we're seeing: the return of outbreaks. Game theory reveals another pattern: For highly contagious diseases, vaccination rates tend to decline rapidly following safety concerns, while recovery occurs much more slowly. This, too, is a mathematical property of the system because decline and recovery have different incentive structures. When safety concerns arise, many parents get worried at the same time and stop vaccinating, causing vaccination rates to drop quickly. But recovery is slower because it requires both rebuilding trust and overcoming the free rider problem – each parent waits for others to vaccinate first. Small changes in perception can cause large shifts in behavior. Media coverage, social networks and health messaging all influence these perceptions, potentially moving communities toward or away from these critical thresholds. Mathematics also predicts how people's decisions about vaccination can cluster. As parents observe others' choices, local norms develop – so the more parents skip the vaccine in a community, the more others are likely to follow suit. Game theorists refer to the resulting pockets of low vaccine uptake as susceptibility clusters. These clusters allow diseases to persist even when overall vaccination rates appear adequate. A 95% statewide or national average could mean uniform vaccine coverage, which would prevent outbreaks. Alternatively, it could mean some areas with near-100% coverage and others with dangerously low rates that enable local outbreaks. All this means that the dramatic fall in vaccination rates was predicted by game theory – and therefore more a reflection of system vulnerability than of a moral failure of individuals. What's more, blaming parents for making selfish choices can also backfire by making them more defensive and less likely to reconsider their views. Much more helpful would be approaches that acknowledge the tensions between individual and collective interests and that work with, rather than against, the mental calculations informing how people make decisions in interconnected systems. Research shows that communities experiencing outbreaks respond differently to messaging that frames vaccination as a community problem versus messaging that implies moral failure. In a 2021 study of a community with falling vaccination rates, approaches that acknowledged parents' genuine concerns while emphasizing the need for community protection made parents 24% more likely to consider vaccinating, while approaches that emphasized personal responsibility or implied selfishness actually decreased their willingness to consider it. This confirms what game theory predicts: When people feel their decision-making is under moral attack, they often become more entrenched in their positions rather than more open to change. Understanding how people weigh vaccine risks and benefits points to better approaches to communication. For example, clearly conveying risks can help: The 1-in-500 death rate from measles far outweighs the extraordinarily rare serious vaccine side effects. That may sound obvious, but it's often missing from public discussion. Also, different communities need different approaches – high-vaccination areas need help staying on track, while low-vaccination areas need trust rebuilt. Consistency matters tremendously. Research shows that when health experts give conflicting information or change their message, people become more suspicious and decide to hold off on vaccines. And dramatic scare tactics about disease can backfire by pushing people toward extreme positions. Making vaccination decisions visible within communities – through community discussions and school-level reporting, where possible – can help establish positive social norms. When parents understand that vaccination protects vulnerable community members, like infants too young for vaccines or people with medical conditions, it helps bridge the gap between individual and collective interests. Health care providers remain the most trusted source of vaccine information. When providers understand game theory dynamics, they can address parents' concerns more effectively, recognizing that for most people, hesitancy comes from weighing risks rather than opposing vaccines outright. This article is republished from The Conversation, a nonprofit, independent news organization bringing you facts and trustworthy analysis to help you make sense of our complex world. It was written by: Y. Tony Yang, George Washington University and Avi Dor, George Washington University Read more: Texas records first US measles death in 10 years – a medical epidemiologist explains how to protect yourself and your community from this deadly, preventable disease Driving the best possible bargain now isn't the best long-term strategy, according to game theory Measles is one of the deadliest and most contagious infectious diseases – and one of the most easily preventable The authors do not work for, consult, own shares in or receive funding from any company or organization that would benefit from this article, and have disclosed no relevant affiliations beyond their academic appointment.
